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Abstract: 
γ- aminobutyric acid type B (GABAB) receptor is an allosteric complex made of two 
subunits, GABAB1 and GABAB 2. GABAB2 plays a major role in the coupling to 
G-protein whereas GABAB1 binds GABA. It has been shown that GABAB receptor 
activates ERK1/2 in neurons of the central nervous system, but the molecular 
mechanisms underlying this event are poorly characterized. Here, we demonstrate that 
activation of GABAB receptor by either GABA or the selective agonist baclofen 
induces ERK1/2 phosphorylation in cultured cerebellar granule neurons. We also show 
that CGP7930, a positive allosteric regulator specific of GABAB 2, alone can induce 
the phosphorylation of ERK1/2. PTX, a Gi/o inhibitor, abolishes both baclofen and 
CGP7930-mediated ERK1/2 phosphorylation. Moreover, both baclofen and CGP7930 
induce ERK-dependent CREB phosphorylation. Furthermore, by using LY294002, a 
PI-3 kinase inhibitor, and a C-term of GRK-2 that has been reported to sequester Gßγ 
subunits, we demonstrate the role of Gßγ in GABAB receptor mediated-ERK1/2 
phosphorylation. In conclusion, the activation of GABAB receptor leads to ERK1/2 
phosphorylation via the coupling of GABAB2 to Gi/o and by releasing Gßγ subunits 
which in turn induce the activation of CREB. These findings suggest a role of 
GABAB receptor in long-term change in the central nervous system. 
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1. Introduction 
γ-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the central 
nervous system [1, 2]. It mediates fast synaptic inhibition through GABAA and 
GABAC ionotropic receptors as well as slow and prolonged synaptic inhibition 
through the metabotropic GABAB receptor [3]. GABAB receptor mediates both 
presynaptic inhibition of neurotransmitter release and post-synaptic inhibition of 
neuronal excitability [4, 5]. Accordingly, GABAB receptor is involved in various types 
of epilepsy, nociception and drug addiction. Activation of the receptor also has 
myorelaxant activity that are commonly used to treat spasticity associated with 
multiple sclerosis [2, 6] 
GABAB receptor belongs to the class C of G-protein coupled receptors (GPCRs), 
together with metabotropic glutamate (mGlu), extracellular Ca2+-sensing, and some 
pheromone and taste receptors [7]. Each of these receptors is composed of an 
extracellular domain called the Venus flytrap domain (VFT), to which agonists bind, 
and a heptahelical domain (HD), which is responsible for the recognition and 
activation of heterotrimeric G-proteins. Whereas mGluRs and Ca2+-sensing receptors 
exist as homodimers, GABAB receptor is a heterodimer composed of two homologous 
subunits, GABAB1 and GABAB2 [8-11]. 
Heterodimerization of GABAB receptor is a prerequisite for GABAB receptor 
function. The VFT domain of GABAB1 is sufficient for ligand binding [7], but its 
assembly with GABAB2 increases the affinity of GABAB1 for agonists [12]. Although 
GABAB2 does not appear to bind any natural ligand [13], GABAB 1 needs to be 
associated with GABAB2 to reach the cell surface [14]. Agonist binding to the 
GABAB1 VFT domain results in its closure and this is likely responsible for a change 
in the relative position of the two VFT and HD domains [15]. This movement then 
allows activation of G proteins mediated by the HD domains of GABAB2 [16, 17]. 
Recently, a novel class of compounds called GABAB positive allosteric modulators 
(PAM) such as CGP7930, appeared to represent a better therapeutic alternative than 
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the classical agonist [18, 19]. Although CGP7930 alone was reported to be inactive in 
several assays, direct activation of the receptor by this positive allosteric modulator 
acting in the HD domain of GABAB2 have also been observed [20]. 
Functional GABAB receptor is predominantly coupled to heterotrimeric Gi/o-type 
protein since most of GABAB receptor-mediated effects are inhibited by pertussis 
toxin (PTX) [21, 22]. Upon activation of the G protein, the Gβγ complex represses 
Ca2+ influx by inhibiting Ca2+ channels [23] and triggers K+ channels opening [24, 25]. 
In the mean time, the Gαi/o subunits modulate the level of cyclic adenosine 
monophospate (cAMP) by regulating adenylate cyclase activities [26]. 
Protein phosphorylation plays a critical role in synaptic plasticity, learning and 
memory in vertebrates [27]. The Extracellular signal-Regulated protein Kinases 1/2 
(ERK1/2), also known as p42/44 mitogen-activated protein kinase (MAPK), signaling 
cascade plays important roles in the modulation of long-term potentiation in area CA1 
of the hippocampus and is required for several forms of learning and memory [28]. 
Recently, it has been reported that GABAB receptor induces ERK1/2 phosphorylation 
in the CA1 area of mouse hippocampus [29]. Regulation of ERK1/2 signaling cascade 
by GPCRs is highly complex and cell type-specific [30], and the mechanism of 
GABAB receptor-mediated ERK1/2 phosphorylation is still poorly understood. 
Furthermore, GABAB receptor is reported to bind to the transcription factor 
CREB2(cAMP responsive element binding protein-2)/ATF4(activating transcription 
factor 4) through coiled-coil interactions [31-33]. Nuclear translocation of CREB2 is 
also observed following GABAB receptor activation [31, 33]. The physiological 
significance for GABAB receptor activation-induced CREB2 translocation awaits 
elucidation.  
In the current study, we examine the role of GABAB receptor in the regulation of 
ERK1/2 and CREB phosphorylation in cultured cerebellar granule neurons. We find 
that selective GABAB receptor activation induces ERK1/2 phosphorylation that in turn 
mediates CREB phosphorylation. We also show that this effect occurs via the 
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GABAB2 coupling to Gi/o proteins by releasing Gβγ subunits. Interestingly, we show 
for the first time that selective activation of GABAB2 is sufficient to induce CREB 
phosphorylation.  
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2. Materials and Methods 
2.1 Materials 
GABA was obtained from Sigma (Shanghai, China). Baclofen was purchased 
from Tocris (Fisher-Bioblock, Illkrich, France). GP54626, CGP7930, Pertussis toxin 
(PTX) were purchased from Calbiochem (US and Canada). Fetal bovine serum, 
culture medium, and other solutions used for cell culture were from Invitrogen 
(Shanghai, China). LY294002 and U0126 were purchased from Cell Signaling 
Technology (Beverly, MA). pRK5 plasmids encoding wild-type GABAB 1 and 
GABAB2 with an epitope tag at their N-terminal ends under the control of a 
cytomegalovirus promotor were described previously [14]. The 
pcDNA3-c-myc-CD8-βARK plasmid, which was composed of the CD8 antigen 
membrane receptor and a domain containing the G-protein βγ subunit-binding site of 
GRK2, was a generous gift from Dr. M. De Waard.  
2.2 Primary cerebellar granule neuronal cultures  
Primary cultures of cerebellar cells were prepared as previously described [34]. 
Briefly, 1-week-old newborn mice were decapitated and cerebellum-dissected. The 
tissue was then gently triturated using fire-polished Pasteur pipettes, and the 
homogenate was centrifuged at 500rpm. The pellet was resuspended and plated in 
tissue culture dishes previously coated with poly-L-ornithine. Cells were maintained 
in a 1:1 mixture of DMEM and F-12 nutrient (Life Technologies, Gaithersburg, MD), 
supplemented with glucose (30mM), glutamine (2mM), sodium bicarbonate (3mM) 
and HEPES buffer (5mM), decomplemented fetal calf serum (10%), and 25mM KCl 
to improve neuronal survival. Three-days-old cultures contained 1.25 x 10 5 cells/cm2. 
2.3 Cell culture and transfection 
Human embryonic kidney HEK293 were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum and transfected by 
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electroporation as described previously [35]. Cells (10 x106) were transfected with 
plasmid DNA containing the cDNAs encoding GABAB1 (4µg) or GABAB2 (4µg), and 
completed to a total amount of 10µg of plasmid DNA with the pRK5 empty vector. 
2.4 Western blot analysis 
Cell lysates from cultures were sonicated, and protein concentrations were 
determined using the Bradford reagent (Bio-Rad Laboratories LTD, Hertfordshire, 
UK). Equal amounts of protein (20µg) were resolved by SDS-PAGE on 12% gels. 
Proteins were transferred to polyvinylidene fluoride membranes (Millipore, Bedford, 
MA) and blocked in blocking buffer (5% nonfat dry milk in TBS and 0.1% Tween 20) 
for 1 hr. The blots were then incubated with the primary rabbit polyclonal antibodies 
against phospho-ERK1/2 (1:1000; Cell Signaling Technology, Beverly, MA), or with a 
rabbit polyclonal antibodies against the total ERK1/2 (1:1000; Cell Signaling 
Technology), overnight at 4°C. This was followed by 1 hr incubation with goat 
anti-rabbit horseradish peroxidase (HRP)-linked secondary antibodies (1:20000; Cell 
Signaling Technology). Immunoblots were revealed using the enhanced 
chemiluminescence reagents (Pierce, USA) and visualized using the X-Ray film. The 
density of immunoreactive bands was measured using NIH image software, and all 
bands were normalized to percentages of control values. 
2.5 Drug treatment 
Cultures were washed once with HBS (Ca2+ free) and preincubated at 37°C with 
HBS for 60 min. Cells were treated by adding freshly made drugs to the HBS. At the 
end of the treatment, cells were washed quickly with ice-cold PBS, pH 7.4 (Ca2+ free), 
lysed with 200µL lysis buffer and placed immediately on ice. The cell monolayer was 
rapidly scraped in ice-cold lysis buffer. Drugs were dissolved in HBS with or without 
dimethyl sulfoxide (DMSO) or/and alcohol. Whenever DMSO or/and alcohol were 
used, HBS containing the same concentration of DMSO or/and alcohol were used as 
the control vehicle.
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3. Results 
3.1. Activation of GABAB receptor increases ERK1/2 phosphorylation in neurons  
We first studied the effect of GABA and the GABAB-selective agonist baclofen, 
on ERK1/2 phosphorylation in cultured mouse cerebellar granule neurons (CGNs). We 
found that GABA at 100µM caused a rapid and transient increase in ERK1/2 
phosphorylation with no changes in ERK1/2 expression levels (Fig. 1A, upper panel). 
ERK1/2 phosphorylation peaked at 10min and then decreased. Similar results were 
obtained with baclofen at 100µM (Fig. 1A, lower panel). These data showed that the 
activation of GABAB receptor leads to increased ERK1/2 phosphorylation in CGNs.  
To demonstrate that ERK1/2 phosphorylation occurs via the specific activation of 
GABAB receptor, we evaluated the effect of the GABAB receptor selective antagonist 
on baclofen-induced ERK1/2 phosphorylation in CGNs. Cells were pretreated for 
20min with GABAB receptors antagonist, CGP54626 (10µM) and then stimulated 
with baclofen (100µM) for 10min. We found that this antagonist blocked 
baclofen-induced ERK1/2 phosphorylation without to alter ERK1/2 expression levels 
(Fig. 1B), thus demonstrating that GABAB receptor activation contributes to the 
baclofen-induced ERK1/2 phosphorylation in CGNs. 
3.2 GABAB receptor-mediated ERK1 /2 phosphorylation occurs through the 
coupling of GABAB2 to Gi/o protein  
GABAB receptor, reported as a Gi/o protein-coupled receptor activates its 
downstream effectors through coupling of GABAB 2 subunits towards G proteins [22, 
23]. Recently, it was demonstrated that CGP7930, a positive allosteric modulator 
(PAM) of the GABAB receptor not only modulates GABAB receptor activity by 
directly acting on GABAB2 HD domain but also activates GABAB 2 when expressed 
alone [36]. To evaluate whether GABAB receptor-mediated ERK1/2 effect occurs 
through GABAB 2 coupling to G protein, we then studied the effect of CGP7930 on 
ERK1/2 phosphorylation in CGNs. CGP7930 at a concentration of 50µM caused a 
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rapid, transient and strong increase in ERK1/2 phosphorylation in CGNs (Fig. 2A). 
ERK1/2 phosphorylation levels induced upon CGP7930 treatment peaked at 10 min 
prior to decreasing gradually to the basal level. Pretreatment of CGNs with 
CGP54626 even at the concentration of 100µM did not abolish CGP7930-induced 
ERK1/2 phosphorylation (Fig. 2A, inset panel). These results demonstrate that 
GABAB2 directly activates ERK1/2 pathway. In addition, the required association of 
GABAB1 with GABAB2 to reach the cell surface [14] indicates that GABAB receptor 
mediated- ERK1/2 phosphorylation in CGNs occurs through GABAB2 coupling to G 
protein.  
We further verified that GABAB receptor mediated-ERK1/2 phosphorylation is 
also regulated through coupling of Gi/o protein by using pertussis toxin (PTX). 
Neurons were pretreated with PTX at 200ng/ml for 14-18hrs, and then stimulated for 
10 min with 100µM baclofen or 50µM CGP7930 (Fig. 2B). Under those 
circumstances, PTX inhibited baclofen or CGP7930 -induced ERK1/2 phosphorylation 
in CGNs (Fig. 2B), demonstrating that baclofen or CGP7930 induced ERK1/2 
activation via Gi/o proteins. 
We confirmed the observed GABAB receptor-mediated ERK1/2 phosphorylation in 
HEK293 cells transfected with both GABAB1 and GABAB2, or with GABAB2 alone. 
GABA at 100µM caused a rapid and transient ERK1/2 phosphorylation without change 
in ERK1/2 levels in cells expressing both GABAB1 and GABAB2 whereas it had no 
effect on the mock-transfected cells (cells transfected with pRK5 empty vector) (Fig. 
3A). CGP7930 alone also induced ERK1/2 phosphorylation (Fig. 3B), and this effect 
was not antagonized by a CGP54626 pre-treatment of the cells (Fig. 3B, inset panel). 
Pretreatment of the cells with PTX blocked both GABA and CGP7930-induced 
ERK1/2 phosphorylation (Fig. 3B). These results demonstrate that GABAB 
receptor-mediated ERK1/2 phosphorylation occurs via GABAB2 coupling to G i/o 
protein. In HEK293 cells expressing GABAB2 alone, CGP7930 induced an acute 
phosphorylation of ERK1/2 whereas it had no effect on mock-transfected cells (Fig. 
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4A). Pretreatment of the cells with PTX efficiently reduced CGP7930-mediated 
ERK1/2 phosphorylation with no change in ERK1/2 expression levels (Fig. 4B), thus 
suggesting that the activation of GABAB2 by CGP7930 is sufficient to mediate ERK1/2 
phosphorylation via Gi/o protein.  
Our results in CGNs and in HEK293 cells transfected with GABAB2 alone or 
with both GABAB1 and GABAB2, showed that GABAB receptor induced ERK1/2 
phosphorylation via the coupling of GABAB2 to Gi/o heterotrimeric proteins. 
3.3 Gßγ subunits mediate GABAB receptor-induced ERK1/2 phosphorylation 
To test whether the coupling of GABAB2 to Gi/o protein occurs via Gßγ/PI-3 
kinase to induce ERK1/2 phosphorylation, we treated CGNs with the selective PI-3 
kinase inhibitor, LY294002. Interestingly, the inhibition of the PI-3 kinase pathway 
led to a strong inhibition of both baclofen and CGP7930- induced ERK1/2 
phosphorylation in neurons (Fig. 5A), thus suggesting an important role for Gßγ 
derived from Gi/o proteins.  
We then investigated the role of Gßγ subunits in GABAB receptor-mediated ERK 
activation in HEK293 cells expressing the GABAB receptor. To this end, we used the 
previously characterized Gßγ-scavenger consisting of the C-terminal region of GRK2 
(ßARK) fused to the extracellular and transmembrane domains of CD8 which then 
provides a membrane anchor for ßARK’s C-tail (CD8-ßARK)[37] [38]. The 
overexpression of CD8-ßARK inhibited GABA-induced ERK1/2 phosphorylation in 
HEK293 cells co-expressing both GABAB1 and GABAB2 and CGP7930-induced 
ERK1/2 phosphorylation in HEK293 cells expressing GABAB 2 alone (Fig. 5B). Taken 
together, these results show that GABAB receptor mediates ERK1/2 phosphorylation 
through Gßγ subunits. 
3.4 GABAB receptor-mediated ERK1/2 phosphorylation induces CREB 
phosphorylation 
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Phosphorylation of ERK1/2 plays an important role in the regulation of gene 
expression via phosphorylation of nuclear transcription factors [39]. We therefore 
tested the response of CREB to the GABAB receptor mediated-ERK1/2 pathway. We 
found that baclofen at 100µM induced a rapid and transient increase in CREB 
phosphorylation in CGNs (Fig. 6A). Baclofen-induced CREB phosphorylation was 
abolished by the pretreatment of CGNs with either CGP54626 (Fig. 6B) or MEK1/2 
inhibitor U0126 (Fig. 6C). Furthermore, the pretreatment of CGNs with U0126 also 
inhibited CGP7930-induced CREB phosphorylation (Fig. 6C). These results show 
that GABAB receptor-mediated CREB phosphorylation occurs through the ERK1/2 
pathway. 
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4. Discussion 
The main findings of the present study concern the mechanism of GABAB 
receptor-mediated ERK1/2 phosphorylation. We show that: 1) GABAB receptor 
activation leads to increased ERK1/2 phosphorylation in cultured cerebellar granule 
neurons which in turn induces CREB phosphorylation; 2) selective activation of 
GABAB2 by CGP7930 is sufficient for ERK1/2 activation in both cultured cerebellar 
neurons and HEK293 cells transfected with GABAB2 alone or in the presence of 
GABAB1; 3) all these effects rely on a PTX-sensitive Gi/o heterotrimeric 
protein-dependent pathway by releasing Gßγ and by implicating PI-3 kinase pathway, 
and 4) both baclofen and CGP7930-mediated CREB phosphorylation is ERK1/2 
dependent. 
Several reports have recently shown that Gi/o-coupled GABAB receptor induced 
ERK1/2 phosphorylation [29, 40-43]. However, the signaling cascades transmitting 
GABAB receptor signals towards ERK1/2 remained unclear. Indeed, the biochemical 
routes linking GPCRs to ERK1/2 are highly complex and cell type-specific [44]. Our 
results demonstrate the role of Gαi/o protein in selective activation of GABAB receptor 
to ERK1/2 signaling. Furthermore, it is well established that PI3 kinase acts 
downstream of Gβγ subunits to mediate GPCR-controlled MAPK activation [45-47]. 
The inhibition of the PI-3 kinase leading to a strong inhibition of baclofen-induced 
ERK1/2 phosphorylation in neurons suggests an important role for Gßγ derived from 
Gi/o proteins for GABAB receptor-mediated ERK1/2 activation.  
We showed that GABAB receptor-mediated ERK1/2 activation requires the 
presence of GABAB 2. These results are compatible with a recent study where 
GABAB1 has been reported to reach the cell surface by co-expression with GABAA 
receptors γ2S subunits in heterologous cellular systems but failed to stimulate ERK1/2 
phosphorylation in the absence of GABAB2 [43]. Furthermore, CGP7930, a positive 
modulator of GABAB receptor, was reported to potentiate GABAB receptor activity 
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by interacting with HD domain of GABAB2 [36]. However, the effect of CGP7930 
alone on GABAB receptor activity is controversial. Meanwhile, CGP7930 produced 
little or no stimulation of the GABAB receptor activity in some studies [18], others 
show that CGP7930 alone can stimulate inositol phosphate accumulation in HEK293 
cells co-expressing the GABAB receptor and the chimeric G-protein Gqi9 [36]. Here, 
we observed CGP7930 alone displays an intrinsic agonist activity on GABAB receptor 
mediated-ERK1/2 activation in both CGNs and HEK293 cells expressing GABAB 
receptor. Competitive antagonist of GABAB receptors such as CGP54626 that binds 
on GABAB1 did not block the CGP7930-mediated ERK1/2 phosphorylation, 
suggesting that GABAB2 activation is sufficient to induce ERK1/2 activation. 
CGP7930-mediated ERK1/2 phosphorylation in HEK-293 cells expressing GABAB2 
alone is compatible with the effect of CGP7930 on inositol phosphate accumulation in 
HEK-293 expressing GABAB2 alone [36].  
Several studies suggested that GABAB receptor plays an important role in 
memory processing. For example, mice lacking the GABAB1 [25] or the GABAB2 
subunit [48] suffer from severe memory impairment. Increasing evidence has shown 
that ERK1/2 plays an important role in long-term synaptic plasticity and memory 
through regulating protein synthesis and gene expression [49, 50]. Stimulation of 
CREB is also critical for long term potentiation [51] through either ERK1/2 or p38 
pathway [52, 53]. In our study, we demonstrate that CREB phosphorylation is 
induced by selective activation of GABAB receptor via an ERK1/2-dependent pathway. 
These data suggest a role of the ERK/CREB pathway in GABAB receptor-mediated 
long-term synaptic plasticity and memory.   
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Figure Legends: 
Figure 1. Activation of GABAB receptor increases ERK1/2 phosphorylation in 
cultured mice cerebellar granule neurons. A, Upper panel, time course of the 
endogenous ERK1/2 phosphorylation after incubation of GABA (100µM). Data 
represent the mean ± SEM from at least five independent experiments. Lower panel, 
typical immunoblots used to quantify the phosphorylated ERK1/2 (pERK1/2). B, 
Effects of the antagonist CGP54626 on baclofen-induced ERK1/2 phosphorylation. 
CGP54626 (10µM) was incubated for 30 min before and during treatment with 
baclofen (10min). pERK1/2 was quantified as previously in Fig. 1A, and data are the 
mean ± SEM from three independent experiments.  
Figure 2. GABAB receptor-mediated ERK1/2 phosphorylation occurs through the 
coupling of GABAB2 to Gi/o-protein. A, Effect of the, CGP7930 (50µM), a PAM of 
GABAB2 in the increase of ERK1/2 phosphorylation in cultured mice CGNs. Data are 
the mean ± SEM from three independent experiments. Inset, effect of CGP54626 
(100µM) on CGP7930-induced ERK1/2 phosphorylation. B, Inhibitory effect of PTX 
on baclofen- and CGP7930-stimulated ERK1/2 phosphorylation. Data are the mean ± 
SEM from three independent experiments 
Figure 3. GABAB receptor-mediated ERK1/2 phosphorylation in HEK293 cells 
co-expressing both GABAB1 and GABAB2. A, Effect of GABA (100µM) in the 
increase of transient ERK1/2 phosphorylation. Data are the mean ± SEM from five 
independent experiments. B, Inhibitory effect of PTX on GABA- and CGP7930- 
stimulated ERK1/2 phosphorylation. Inset, Effect of CGP54626 (100µM) on 
CGP7930-induced ERK1/2 phosphorylation. Data represent the mean ± SEM from at 
least three independent experiments. 
Figure 4. Activation of GABAB2 increases ERK1/2 phosphorylation in HEK293 cells 
expressing GABAB2 alone. A, Effect of CGP7930 (50µM) in the increase of transient 
ERK1/2 phosphorylation. B, Inhibitory effect of PTX on GABA- and CGP7930- 
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stimulated ERK1/2 phosphorylation. Data are the mean ± SEM from at least four 
independent experiments.  
Figure 5. Gßγ subunit mediates GABAB receptor-induced ERK1/2 phosphorylation. 
A, Effect of LY294002 (20µM) on GABAB receptor-mediated ERK1/2 phosphorylation 
induced by baclofen (100µM) or CGP7930 (50µM) in CGNs. B, Effect of 
over-expression of c-myc-tagged CD8-ßARK, Gßγ subunits inhibiting peptide, on 
GABA and CGP7930-induced ERK1/2 phosphorylation in HEK293 cells expressing 
the heterodimer GABAB and GABAB2 alone, respectively. Data are the mean ± SEM 
from at least four independent experiments. 
Figure 6. GABAB dependent CREB phosphorylation is mediated by ERK1/2 
phosphorylation. A, The effect of baclofen (100µM) on CREB phosphorylation 
(pCREB) was determined by immunoblotting, and quantified as previously for 
pERK1/2 in Figure 1A. B, Effect of CGP54626 (10µM) on baclofen-induced CREB 
phosphorylation. C, Effects of U0126 (10µM) on baclofen- or CGP7930- mediated 
ERK1/2 and CREB phosphorylation in CGNs. Data are the mean ± SEM from at least 
four independent experiments. 
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